title: Efficacy of Hepatitis B vaccine in those who lost Hepatitis B surface antigen during follow-up: Efficacy of HBV vaccine in those who lost HBsAg.
abstract: BACKGROUND
  The level of HBsAg in some chronic hepatitis B virus (HBV)-infected individuals may decline over time so that it is not detectable in serum.
  
  
  OBJECTIVE
  To assess the efficacy of HBV vaccine in those who lost their HBsAg without seroconverssion to anti-HBs antibody.
  
  
  METHODS
  From April 1993 to December 2008, of 1603 chronic HBV-infected individuals, 34 (22 men and 12 women) became HBsAg-negative in follow-up visits, with no detectable anti-HBs antibody and HBV DNA in their sera. They received HBV vaccination at 0, 1 and 6 months (case group). Fifty-two subjects (30 men and 22 women) who were negative for HBsAg, anti-HBs and anti-HBc antibody, received HBV vaccination according to the said schedule (control group). Anti-HBs antibody was assessed one month after the last dose of vaccination in the both groups.
  
  
  RESULTS
  The mean±SD age of the case and control groups was 38±12.7 and 33.4 ± 8.6 years, respectively (p = 0.07). The sex distribution between these two groups were similar (p = 0.652). The mean ± SD years of follow-up for the case group was 7.6 ± 4.5 years. Anti-HBs antibody level ≥ 10 IU/L was found in 8 (24%) subjects in the case group and in 45 (87%) in the control group (p < 0.001). The mean±SD anti-HBs antibody level in the case group was 68 ± 32.66 and in the control group 344.6 ± 38.9 IU/L (p < 0.001).
  
  
  CONCLUSIONS
  We found that nearly 24% of chronic HBsAg-positive subjects who lost their HBsAg responded to HBV and the remaining cases need to be followed for occult HBV infection.
authors.affiliation: Infectious Diseases Research Center, Babol University of Medical Sciences, Babol, IR Iran.
authors.forename: Hassan
authors.initials: H
authors.lastname: Taheri
authors.forename: Mohammad Reza
authors.initials: MR
authors.lastname: Hasanjani Roushan
authors.forename: Mohammad Jafar
authors.initials: MJ
authors.lastname: Soleimani Amiri
authors.forename: Mohammad
authors.initials: M
authors.lastname: Pouralijan
authors.forename: Ali
authors.initials: A
authors.lastname: Bijani
references.citation: World J Gastroenterol. 2008 Apr 14;14(14):2288-9
references.pmid: 18407613
references.citation: N Engl J Med. 1985 Jan 31;312(5):270-6
references.pmid: 2981408
references.citation: Hepatology. 2004 Nov;40(5):1072-7
references.pmid: 15486926
references.citation: Ren Fail. 2006;28(8):729-35
references.pmid: 17162434
references.citation: Hepatogastroenterology. 2003 Sep-Oct;50(53):1474-7
references.pmid: 14571767
references.citation: Clin Microbiol Rev. 1999 Apr;12(2):351-66
references.pmid: 10194463
references.citation: Hum Vaccin. 2008 Sep-Oct;4(5):379-83
references.pmid: 18398305
references.citation: Hepatology. 1988 Jul-Aug;8(4):766-70
references.pmid: 2968945
references.citation: Scand J Infect Dis. 2000;32(3):315-6
references.pmid: 10879605
references.citation: J Infect. 2001 Oct;43(3):187-90
references.pmid: 11798257
references.citation: JAMA. 1987 Sep 4;258(9):1193-5
references.pmid: 2957523
references.citation: J Infect. 2000 Sep;41(2):130-6
references.pmid: 11023756
references.citation: Rev Gastroenterol Peru. 2005 Jul-Sep;25(3):254-8
references.pmid: 16237469
references.citation: Mikrobiyol Bul. 2007 Apr;41(2):227-33
references.pmid: 17682709
references.citation: J Prev Med Public Health. 2005 May;38(2):170-4
references.pmid: 16315754
references.citation: J Med Virol. 1992 Mar;36(3):180-3
references.pmid: 1532979
references.citation: Ann Intern Med. 2001 Nov 6;135(9):759-68
references.pmid: 11694101
references.citation: J Gastroenterol Hepatol. 1995 Mar-Apr;10(2):192-7
references.pmid: 7787166